Peanut-Allergic Toddlers Also Benefit From Oral Immunotherapy With Palforzia

New research findings show that an FDA-approved oral immunotherapy for older children and adolescents safely increased peanut protein tolerance in peanut-allergic children aged 1-3 years.

Related Keywords

Lubbock ,Texas ,United States ,United Kingdom ,Kentucky ,Jamesa Tarbox , ,American College Of Allergy ,Drug Administration ,Texas Tech University Health Sciences Center ,American College ,Annual Scientific Meeting ,Medscape Medical News ,Evelina London Children ,Peanut Allergy ,Eanut Anaphylaxis ,Allergy To Peanuts ,Food Allergy ,Biologic Therapy ,Immunotherapy ,Otolaryngology ,Nt Ears ,Nose ,Throat ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Allergy ,Asthma ,Sthmatic ,Allergens ,Immunology ,Acute Respiratory Distress Syndrome ,Cute Respiratory Distress Syndrome Ards ,Adult Respiratory Distress Syndrome ,Cards ,Adolescent Medicine ,Quality Of Life ,Pol ,Sea ,